Onxeo: Combined Ordinary and Extraordinary General Meeting on April 15, 2015

Procedures for obtaining preparatory documents
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:

Onxeo’s (Paris:ONXEO) (NASDAQ OMX:ONXEO) shareholders are invited to attend the
Combined Ordinary and Extraordinary General Meeting to be held at 9:30am on
April 15, 2015 at the company's head office (49 Boulevard du Général Martial
Valin, F-75015 Paris, France).

The official notice of the Meeting was published in the French Republic's
Bulletin des Annonces Légales Obligatoires ("Bulletin of Mandatory Legal
Announcements") dated

March 11th, 2015 and contains the agenda, the draft resolutions and information
on attendance and voting procedures. It can be viewed on the company's web site
at: http://www.onxeo.com/eng/Investisseurs/Shareholders-Meetings.

Documents related to the meeting are available to shareholders, under the
conditions set out in the current legislation, and will also be posted on the
company’s website at www.onxeo.com from March 25th, 2015 onwards.

Shareholders may, in accordance with Articles R.225-88 and R.225-89 of the
French Commercial Code, consult the above-mentioned documents (together with the
information specified in Articles R.225-81 and R.225-83 of the said Code) at the
company's head office or request supply of the said documents and information by
post/mail to a duly indicated postal/mailing or electronic address by writing to
Onxeo (Direction Financière – 49 boulevard du Général Martial Valin, 75015
Paris, France), faxing to +33 1 45 58 08 81 or sending an e-mail to
ag2015@onxeo.com from March 25th, 2015 onwards.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive
preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).
Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol / Sophie Colin – Alize RP
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62